{
    "medicine_id": "9e6da35ca2487ce498cfed67185e04d43081bcc6",
    "platform_id": "DB08876",
    "metadata": {
        "name": "Elelyso 200 U 5mL Injection powder lyophilized for solution",
        "composition": "200 U 5mL Taliglucerase alfa",
        "clinical_particulars": {
            "therapeutic_indications": "For the treatment of adult Type 1 Gaucher disease",
            "contraindications": {
                "disease": "The most common toxic reaction seen was infusion reactions such as urticaria arthralgia headache and chest pain due to IV administration",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Patient s with Type 1 Gaucher disease have a long term deficiency in the enzyme glucocerebrosidase Taliglucerase alfa is a modified form of glucocerebrosidase and is provided to counter this enzyme deficiency resulting in smaller liver and spleen size and improved thrombocytopenia and anemia",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}